About me
Carrie Nielson is a Director of Epidemiology at Gilead Sciences, where she focuses on regulatory policy for RWE and on rigorous observational research methods that support reliable evidence generation. She collaborates with industry, academic, and regulatory colleagues, including through the DIA Artificial Intelligence Consortium, helping align on AI use-case development, risk-proportionate validation approaches, and defensible oversight and documentation models. Her work centers on translating emerging regulatory expectations into practical, inspection-ready systems and procedures that enable sound adoption of RWE and AI in drug development contexts.
